Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia

Clin Cancer Res. 2016 Aug 1;22(15):3707-9. doi: 10.1158/1078-0432.CCR-16-0372. Epub 2016 Mar 15.

Abstract

The proliferative component of chronic myelomonocytic leukemia, related to an increased sensitivity of myeloid progenitors to granulocyte macrophage-colony stimulating factor, suggests dedicated therapeutic approaches. In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients. Clin Cancer Res; 22(15); 3707-9. ©2016 AACRSee related article by Padron et al., p. 3746.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antinematodal Agents / therapeutic use*
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism*
  • Humans
  • Janus Kinases / metabolism*
  • Leukemia, Myelomonocytic, Chronic / drug therapy*
  • Leukemia, Myelomonocytic, Chronic / metabolism*
  • Nitriles
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • STAT Transcription Factors / metabolism*
  • Signal Transduction / drug effects
  • Treatment Outcome

Substances

  • Antinematodal Agents
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT Transcription Factors
  • ruxolitinib
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Janus Kinases